

Combining Neuroscience And Immunology: Exploring The Neuro-immune Circuitry Behind Itch And Inflammation By Targeting IL-13R α 1 With Eblasakimab

Ferda Cevikbas, PhD



ASLAN Pharmaceuticals, California, USA, and Singapore

Atopic dermatitis (AD) is a common, chronic itchy and inflammatory skin disease



Up to 13% of children and 7% of adults in developed countries are affected. AD causes massive suffering for both patient and family.



Atopic dermatitis is a chronic inflammatory skin disease with a predominant Th2 cell polarisation



IL-4 and IL-13 are key cytokines of Th2 underlined diseases


- Signal through Type 2 receptor on immune and non-immune cells
- drive inflammatory responses in AD
- amplify itch responses through neuronal sensitization

Targeting the IL-4 and IL-13 pathway in AD is a clinically proven approach




- Approved treatments in AD including dupilumab and tralokinumab block different aspects of the IL-4/ IL-13 pathway
- Blocking different parts of the receptor pathway can have different downstream signaling effects which may yield in
 - molecular differentiation between drugs
 - different downstream effects in disease

Eblasakimab has a unique MoA via its targeting of the IL-13R α 1 subunit




- Eblasakimab is a human IgG4 antibody which targets the human IL-13R α 1 subunit of the Type 2 receptor complex
- By blocking the IL-13R α 1, eblasakimab blocks IL-4 and IL-13 signaling through the Type 2 receptor only and does not interfere with the Type 1 receptor

Why unique translational models are needed to understand differentiation?



Bench



Bedside

- Monoclonal human-specific antibodies limit research with non-human species
- Utilizing human tissue or human-derived (healthy and patient) “inflamed” cells or neurons
- Translational gap between mouse and human neurons
- Emerging translational tools to advance mechanistic properties of eblasakimab and potentially compare/differentiate to other pathway targets

Translational research questions



What is the differentiated mechanism of eblasakimab targeting IL-13R α 1 versus IL-4R α in skin diseases?




Can eblasakimab directly block neuronal multi-sensitized itch and provide rapid itch relief?



Can we expand eblasakimab *in other indications with translational science?*


What is the differential signaling between the Type 1 and Type 2 receptor pathways?



- **Th1 and Th2 cytokine levels** upon IL-4R α vs IL-13R α 1 receptor blockade were analyzed with MesoScale Discovery Platform.
- PBMCs obtained from 10 patients with AD were treated with anti-IL-13R α 1 (eblasakimab) or anti-IL-4R α (RnD Systems).


PBMC, peripheral blood mononuclear cells.

IL-13R α 1 blockade results in lower levels of key cytokines implicated in Th2-driven inflammation compared to IL-4R α blockade




IL, interleukin; MCP, monocyte chemoattractant protein; TARC, thymus activation regulated chemokine.
Antibody targeting IL4R α supplied by R&D Systems. Demonstrated to block IL-4 and IL-13 signaling through Type 1 and Type 2 receptors.

IL-13R α 1 blockade prevents subsequent expression changes of Th1 cytokines



GM-CSF, granulocyte-macrophage colony-stimulating factor; IP, Interferon gamma-induced protein; TNF, tumor necrosis factor; TSLP, thymic stromal lymphopoietin.
ªAntibody targeting IL4R α supplied by R&D Systems. Demonstrated to block IL-4 and IL-13 signaling through Type 1 and Type 2 receptors.




Validation of AD derived PBMC findings in AD skin biopsies



Methods:


- 4mm skin punch biopsies from AD patients were collected for ex vivo organ culture.
- Skin punches were treated for 48h with either **ebulasakimab**, **dupilumab** or **isotype** control to collect the supernatant for secreted cytokines/chemokines with a multiplex cytokine array (Eve Technologies).

Similar inhibitory effects were observed for Eotaxin, CCL-22 and CCL-5




Preliminary data from ongoing experiments

Pro-inflammatory TH2 cytokines reduced more by eblasakimab as compared to dupilumab



Preliminary data from ongoing experiments

Other AD relevant mediators were tendentially downregulated by eblasakimab in AD lesional skin



Preliminary data from ongoing experiments


Clinical Significance

These results suggest that ***targeting different subunits of the same molecular pathway*** can lead to different clinical outcomes

Selective blockade of the IL-13R α 1 subunit by eblasakimab is a promising therapeutic approach compared to IL-4R α blockade as it **circumvents increased levels of Th1 and Th2 cytokines**

Eblasakimab may offer a **differentiated therapeutic approach** to treat AD by **potentially more efficient blockade of the Type 2 receptor and sparing the Type 1 receptor**

Translation to the clinic: Eblasakimab monthly dosing regimen achieved comparable efficacy to dosing every 2 weeks in the Phase 2b AD study



- A Phase 2b dose-ranging dose study evaluated the safety and tolerability for eblasakimab vs placebo in adult patients with moderate-to-severe AD
- Improvement of EASI scores was significantly greater for eblasakimab at week 16 for eblasakimab doses 600mg Q4W doses, 300mg Q2W vs placebo
- Efficacy in monthly dosing is supported by translational data on differentiated and unique MoA

Translational research questions



What is the differentiated mechanism of eblasakimab targeting IL-13R α 1 versus IL-4R α in skin diseases?




Can eblasakimab directly block neuronal multi-sensitized itch and provide rapid itch relief?



Can we expand eblasakimab *in other indications with translational science?*

Itch from a philosophical view



Chronic itch is a persistent sensation lasting more than 6 weeks

Impacts on quality of life

- Sleep disruptions
- Impaired daytime activities
- Decreased school performance in children
- Increased rates of ADHD


Causes

Neuropathic
Psychogenic

Dermatological
Systemic



Sensing itch in the skin



The sensation of itch is carried by unique sensory neurons called **unmyelinated C-fibers**



Cutaneous sensory neurons, which innervate the skin, transmit itch & carry the signal along axons to the spinal cord and brain




These neurons are a **subset of pain-transmitting** primary afferents




The process entails **complex inhibitory and excitatory control between itch and pain** circuitry

Translational neuronal itch models to assess anti-pruritic effects




Live-cell calcium imaging output: Neuronal responses




Eblasakimab reduced enhanced neuronal itch responses to IL-4 and IL-13

Neuronal responses to BAM8-22



Neuronal responses to PAMP-20



ebla, eblasakimab.

* $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$; error bars indicate standard error of mean

Conclusions

- Human sensory neurons are sensitized by Th2 cytokines to pruritogens
- IL-4 and IL-13 **do not necessarily function as redundant cytokines**
- Eblasakimab **potently inhibits both IL-4 and IL-13-** driven effects

Data provide **a mechanistic basis for the reduction of itch observed in patients** with moderate-to-severe AD and potentially suggests broad anti-pruritic efficacy across different Th2 inflammatory diseases

Translational research questions



What is the differentiated mechanism of eblasakimab targeting IL-13R α 1 versus IL-4R α in skin diseases?




Can eblasakimab directly block neuronal multi-sensitized itch and provide rapid itch relief?



Can we expand eblasakimab in other indications with translational science?

The PCLS model: Precision Cut Lung Slices




Human PCLS from healthy donors were treated for 48 hours with cytokines

Airway responsiveness was tested with increasing doses of Methacholine (MCh), followed by a single dose of Formoterol (therapy for dilation)

Chronic **O**bststructive **P**ulmonary **D**isease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms due to abnormalities of the:
Airways (bronchitis, bronchiolitis), and/or Alveoli (emphysema) which causes persistent, often progressive, airflow obstruction

Eblasakimab reduces airway constriction and enhances dilution in PCLS from healthy donors



Preliminary data from ongoing experiments


Significance of COPD model

IL-4 and IL-13 combined pre-treatment of PCLS results in **increased bronchoconstriction of the airways** tested in the PCLS with Methacholine

Both cytokines **delay the kinetics of airway dilation to Formoterol** suggesting rapid changes of airway responsiveness with 48 hours of treatment

Eblasakimab significantly blocks the IL-4/IL-13 increased bronchoconstriction as well as rapidly improves responses to Formoterol as compared to cytokine- treated PCLS

Translational models help elucidate the unique mechanism of action and differentiated effects of eblasakimab




Blood cells and skin biopsy from patients with AD

Differentiated therapeutic approach through unique MoA – potential for more efficient blockade and sparing Type 1 receptor



Cultured human dorsal root ganglion neurons

Eblasakimab reduced IL-4 and IL-13-induced neuronal sensitization to itch and neuronal hyperactivity



COPD model: human precision cut lung slices

Eblasakimab significantly blocked the IL-4/IL-13 increased bronchoconstriction and enhanced dilation in human PCLS

Acknowledgements

ASLAN Pharmaceuticals

Drs Shawn and Madan Kwatra


Monasterium Laboratories

Yannick Miron, Paul Miller, Carl Firth

Dani Guralnick

Mechanobiologix LLC

Prescott Medical Communications Group



Cevikbas F, Lerner EA. *Physiol Rev.* 2020;100(3):945-982.